Say Ahh! Making Sense of Oral Assessments for Mucositis

VBCC - March 2013, Volume 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts
Joanne Growney, MA, RN, ANP-BC, OCN
Rebecca Martin, BSN, RN, OCN
Phyllis McKiernan, RN, MSN, APN-BC
Joan Collela, RN, DNP, APN-BC, NP-C
Claudia Douglas, RN, MA, CNN, APN-C

Background: Chemotherapy and radiation therapy, the mainstays of current cancer treatment, often result in devastating side effects involving the oral cavity. Mucositis, an inflammatory and/or ulcerative lesion of the oral and/or gastrointestinal tract is a common therapy-related toxicity. Mucositis significantly impacts patients’ overall physical and functional well-being, as well as quality of life. There is strong evidence suggesting that the implementation of preventive strategy, such as patient and family education on the importance of oral hygiene practices, can lower the incidence of mucositis. The evidence also suggests that mucositis can be prevented or managed by performing rigorous oral hygiene, leading to lower occurrence in severity and in progressive symptoms. Research suggests that the implementation of preventive strategies such as patient and family education can lower the severity of mucositis symptoms, and the nurse plays a unique role in performing this patient and caregiver education at every opportunity of point of care.

Objective: To develop a standardized patient education booklet for oral assessment, oral hygiene practices, and symptom management of mucositis in populations with cancer.

Methods: The evidence-based practice (EBP) project was initiated using the Johns Hopkins model for the question development and project management. The EBP project will be carried out in phases. The first phase is to standardize an oral assessment tool for mucositis across populations and settings and the development of a practice policy. The mucositis EBP workgroup developed a pilot to gather data on the selected oral assessment tool to show evidence that the tool was endorsed by the staff nurses who were using it. In addition, the workgroup brought the project through the appropriate hospital councils to incorporate the oral assessment guide (OAG) into the daily shift assessment. Included in phase 1, the nurse educator completed the education of all of the nursing staff on oral assessment, oral hygiene, and chart documentation. Next, phase 2 included the development of a standardized patient education and a nursing policy that governs when and how education and assessment are performed. We are now approaching phase 3, in which the mucositis workgroup will be developing standards of treatment based on OAG score, known as the mucositis protocol.

Results: A patient-centered education program on the identification of the signs and symptoms of mucositis and on oral hygiene practices will be accomplished by developing a transdisciplinary EBP team, inclusive of advanced-practice nurses, staff nurses, pharmacists, dieticians, oncologists, dentists, and patient and caregiver representation. This EBP team will identify best educational practices and will incorporate patient preferences for education content, and assure collaborative decision-making among team members. The focus of this project will be the implementation of a patient-centered cancer education program related to oral hygiene practices and the identification of the signs and symptoms of mucositis. Comprehensive oral assessment conducted by the nurse will lead to earlier identification of the signs and symptoms of mucositis. Rapid detection of the onset of mucositis by the patient and the nurse will lead to implementation of interventions that will promote improved patient outcomes. The project goals include patient and caregiver early recognition of the symptoms of mucositis and improved quality of life patient outcomes in the areas of pain, dehydration, and weight loss. Therefore, with the identification, selection, and implementation of the OAG with oral hygiene practices, earlier recognition of mucositis symptoms and early initiation of the appropriate treatment will result. The EBP project has completed phase 1. During this phase, a pilot study was completed on 492 oral assessments. These assessments included 24 registered nurses and 5 advanced-practice nurses. The results of this pilot showed that 82% of users agreed on utilizing the OAG as the assessment tool, because it was thorough. In addition, 86% of the participants felt the tool was user-friendly. In phase 2, the Mucositis EBP workgroup is standardizing the patient education booklet; the nursing policy on performing oral assessment; and oral hygiene practices. A follow-up chart audit performed after the initial nursing staff education on oral assessment documentation showed a 64% increase and was occurring in a policy-compliant manner. Phase 2 included having the workgroup present the new OAG to be placed in the electronic medical record to the hospital informatics council.

Conclusions: At the conclusion of this EBP project, patients and caregivers will be able to demonstrate and articulate an oral assessment, the signs and symptoms of mucositis, and oral hygiene practices. The oncology nurses’ role is intended to enhance cancer care for symptom management. This EBP project of standardizing oral assessment skills, oral hygiene practices, and intervening with a mucositis protocol will become part of the oncology nurses’ armament to aid the patient through the treatment process, thus resulting in enhanced cancer care.

Related Items
Perspectives of Quality Care in Cancer Treatment: A Review of the Literature
Lisa M. Hess, PhD, Gerhardt Pohl, PhD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Is Oral Electrolyte Replacement More Effective than IV Replacement in the Oncology Population?
Rebecca Martin, BSN, RN, OCN, Joanne Growney, RN, MA, ANP-BC
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Cost Considerations for New Oral Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously
Lorie A. Ellis, Zoe Clancy, R. Scott McKenzie, Mekre’ Senbetta
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Cost Analysis of Bortezomib Retreatment Compared with Switching to Carfilzomib in Patients with Relapsed Multiple Myeloma Previously Treated with Bortezomib
Kevin B. Knopf, MD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, MS, Patrick Lefebvre, MA, Liviu Niculescu, MD, Abbie Ba-Mancini, MBA, Esprit Ma, MPH, Mei Sheng Duh, MPH, ScD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Imatinib Can Still Be Used as 1st-Line for Treating Chronic Myelogenous Leukemia
Wesley Wong, PhD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Wait Time and Patient Satisfaction—Improving Outcomes Can Be as Easy as Child’s Play
Julia Whiteker, Ann Bredensteiner
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia
Gluck S, Yardley D, Belk K, Craver C, Cox D, Faria C, University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Tennessee Oncology, PLLC, Nashville, TN; MedAssets, Inc., Charlotte, NC; Eisai Inc., Woodcliff Lake, NJ
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Treatment Modification on Treatment Duration in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
An Assessment of Racial Differences in Toxicities and Supportive Care in Patients with Metastatic Breast Cancer (MBC)
George Dranitsaris, Nancy Beegle, Traci Kalberer, Zhixiao Wang, Claudio Faria, Sibel Blau
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving 5-HT3-RA Therapy throughout Chemotherapy Cycles
Faria C, Nagl N, Powers A. Eisai, Inc. 100 Tice Blvd. Woodcliff Lake, NJ 07667
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology